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ABSTRACT
Through traditional medicine, there were diseases and disorders that previously remained
untreated or were simply thought to be incurable. Since the discovery of mesenchymal stem
cells (MSCs), there has been a flurry of research to develop MSC-based therapy for diseases and
disorders. It is now well-known that MSCs do not typically engraft after transplantation and
exhibit their therapeutic effect via a paracrine mechanism. In addition to secretory proteins, MSCs
also produce extracellular vesicles (EVs), membrane-bound nanovesicles containing proteins, DNA
and RNA. The secreted vesicles then interact with target cells and deliver their contents, impart-
ing their ultimate therapeutic effect. Unlike the widely studied cancer cells, the yield of MSC-
exosomes is a limiting factor for large-scale production for cell-free therapies. Here we summarise
potential approaches to increase the yield of such vesicles while maintaining or enhancing their
efficacy by engineering the extracellular environment and intracellular components of MSCs.
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Introduction
Regenerative medicine itself was a novel idea: using dif-
ferent cell types to restore any damaged, ageing or lost
tissue of the human body. The earliest application of
cellular therapy would date back to World War I, where
blood transfusions were used to save wounded soldiers’
lives, eventually leading to the discovery of hematopoietic
stem cells and then giving rise to stem cell-based thera-
pies. To this day, there are over 6600 stem cell-related
clinical trials underway in the USA alone and many more
internationally (www.ClinicalTrials.gov).
Mesenchymal stem cells (MSCs) are multipotent
cells that can differentiate into various cell types such
as osteoblasts, chondrocytes and adipocytes in vitro [1].
They can be obtained from several sources such as
bone marrow, placenta, adipose tissue, amniotic fluid,
and umbilical cord to name a few [2]. They have been
coined the “paramedics” of the human body, traversing
to injury sites for tissue repair or wound healing [3–5].
In addition to their role in the tissue regeneration,
MSCs are also immune privileged, having the ability
to be introduced to an immune system without elicit-
ing an inflammatory response. But there are risks fac-
tors involved when considering MSCs as a cell-based
treatment. Due to the cells’ multipotency, there is the
chance of tumorigenesis if the regulation of prolifera-
tion/differentiation were to dysfunction. Several studies
have revealed a low engraftment rate of MSCs after
transplantation; yet, their therapeutic effects remain
long after implantation, suggesting that their effects
are achieved through paracrine mechanisms rather
than replacing the lost cells with newly differentiated
cells [6–8]. For example, the conditioned medium
(CM) from MSCs (MSC-CM) was observed to protect
the cardiomyocytes by interrupting mitochondria-
mediated cell death [5]. Several studies have shown
that by altering the culture environment of cells such
as growing in low oxygen atmosphere [9–11] or adding
biomolecules such as brain-derived neurotrophic factor
mimetics or peptides [12–14] could lead to improved
functional effect of the CM. Now it is recognised that
not only do the MSC-CM comprise of cytokines and
growth factors, but it also contains extracellular vesicles
(EVs) that may play a key role in imparting these
effects [9–11,15–17].
Overview of extracellular vesicles
EVs were thought to function solely as the “dumpster”
of cells, a way to dispose of unwanted proteins and
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other molecules, but they have now emerged as one of
the significant mediators in cell–cell communication
for many processes such as immune response, angio-
genesis, proliferation and differentiation [5,6,8,18–21].
There are three widely known EVs: apoptotic bodies,
microvesicles and exosomes. The apoptotic bodies can
be the largest, with their diameters ranging from 800 to
5000 nm, while microvesicles are smaller, between 50
and 1000 nm. Both of these EVs have similar biogen-
esis as they bleb from the cell plasma membrane. The
difference is that the apoptotic bodies bleb from apop-
totic cells while the microvesicles bleb from living cells.
The blebbing of the apoptotic bodies occur indiscrimi-
nately from the apoptotic cells and can contain frag-
mented nuclei, proteins, DNA, miRNA to name a few.
The blebbing of the microvesicles follow an orderly
pattern: trafficking of cellular molecules to the plasma
membrane that result in protrusion of the cell’s surface,
budding then detaching from the membrane.
Exosomes are the smallest, with sizes falling between
30 and 150 nm, and are generated within the cells
through the endolysosomal pathway (Figure 1).
The pathway begins at the plasma membrane, where
the membrane folds inward and then pinches off an
empty intraluminal vesicle [5,6,8,22–26]. The process
of endocytosis continues on the membrane of the
intraluminal vesicle, creating smaller vesicles known
as exosomes. The empty intraluminal vesicle then
matures into a multivesicular body, where exosomes
accumulate. The multivesicular body can either fuse
with the cell’s plasma membrane and release those
exosomes, or mature further into a lysosome, one of
the many essential organelles of a cell [22–26]. This
endolysosomal pathway leading to the generation and
release of exosomes is regulated by a well-defined
mechanism such as the endosomal sorting complex
required for transport (ESCRT) or the Rab proteins
[22–26]. At the same time, the exosomes encapsulate
the MSCs’ cytoplasmic contents of proteins, DNA
and RNA.
Isolation of extracellular vesicles
There are many ways of isolating and purifying EVs from
the CM, eachwith its own pros and cons. Themethods can
include the ultracentrifugation, precipitation, immunoaffi-
nity, size exclusion chromatography and ultrafiltration
[25,27–29]. Ultracentrifugation is considered themost effi-
cient way of obtaining EVs from samples through several
centrifugation steps of increasing speed. Advantages
include low cost and the ability to spin large volumes,
but biggest disadvantage is that the pellet may contain
non-EV contaminants (i.e. lipoprotein complexes or cel-
lular debris) since the method does not specifically discri-
minate between the EVs from other particles (i.e. cellular
debris), especially of similar densities (i.e. lipoprotein com-
plexes) [30]. Additional steps are usually added in the
process to obtain a more homogenous population such
as density gradient, use of a column or ultrafiltration
[25,27–29]. Precipitation is the use of a precipitating
agent to induce the clumping of EVs that is usually sedi-
mented by centrifugation. It is considered a concentration
method, hence the starting volume can be low, but the
introduction of a synthetic material to the sample may not
be ideal for downstream functional applications [25,27–
29]. Immunoaffinity is an isolation method that utilise the
Figure 1. Biogenesis and release of extracellular vesicles, both microvesicles and exosomes (A). The contents of the exosomes are
shown as well (B).
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immobilised antibodies to capture the EVs containing a
specific ligand. Immunoaffinity is commonly used as a
purification step because it is not compatible with large
sample volumes and samples with low EVs must be con-
centrated first [25,27–29]. Size exclusion chromatography
and ultrafiltration have similar working principles, where
the EVs are separated based on size and that is achieved
with Sepharose beads or membrane filter although each
method have its own advantages and disadvantages
[25,27–29]. Size exclusion chromatography can reduce
the EV aggregates that are common with other isolation
protocols but the resulting EV samples are very dilute,
requiring a second step of re-concentration.
Ultrafiltration utilises force to push the sample through
the filter and is often used in combination with other
techniques as it is more time efficient than centrifugation
methods; however, there is the potential loss of EVs due to
trapping in the pore membrane or non-specific binding of
EVs to the membrane (Figure 2). While each isolation
technique comes with its own limitations, there are ways
to overcome those limitations and recommendations have
been proposed previously [25,27–29].
MSC-derived exosomes
MSC-derived exosomes (MSC-exosomes) have been
used as a treatment for diseases and disorders of
many systems such as the cardiovascular, neurological,
musculoskeletal and immune systems [5,6,8,31]. Rats
with traumatic brain injury exhibited significant func-
tional recovery, increased neurite remodelling, angio-
genesis and neurogenesis after treatment with
exosomes [32]. They can ameliorate liver fibrosis,
exert protective effects against acute liver injury and
may enhance the anti-tumour effect against hepatocel-
lular carcinoma [18]. MSC-exosomes have also been
found to inhibit the migration of inflammatory cells,
thus providing a benefit for the autoimmune disease
uveitis [33]. Plenty of studies have shown their thera-
peutic use; however, one caveat is that the generated
exosomes are not a uniform population [34,35]. Their
composition can vary depending on many factors such
as the culture environment, isolation procedures and
their cellular origin, thus leading to a variety of cyto-
kines, DNA and RNA species being encapsulated by
the exosomes. First, the purity of the exosomes must be
established based off the isolation method. Polymeric
precipitation of the exosomes would require some
further purification [18,32] or the ultracentrifugation
of exosomes may need some additional filtering [33].
Different isolation or purification methods can also
yield heterogeneous MSC-exosomes, making it difficult
to compare proteomic studies between them. Second,
the composition of exosomes is closely associated with
the cellular health and condition of the secreting cells
as different molecular signatures are found between
Figure 2. Common methods in isolating the extracellular vesicles. Ultracentrifugation is the method often utilised in experiments
(A). Precipitation involves the use of an agent that allow for the pelleting of EVs (B). Ultrafiltration uses a filter to separate the EVs
from the other molecules based off pore size in the filter (C). Immunoaffinity uses antibody to capture the EVs based on their
surface markers (D). Size exclusion chromatography separate the EVs from the non-EVs molecules with a packed column of certain
materials (E).
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exosomes derived from healthy, ageing, and diseased
cells or their growth environment(s) [36–38].
Nevertheless, considering the complex production
pathway, exosomes generated from MSCs in a well-
defined culture environment could be a powerful ther-
apeutic agent by themselves for cell-free therapy and
circumvent the issue of immune rejection that can
occur in live cell-based therapies.
Potential approaches to improve MSC-exosome
yield and efficacy
A Good Manufacturing Practice-compliant protocol had
been developed for obtaining MSC-derived EVs [39].
Although MSC-derived EVs show promising application
for regenerative therapies, their use is often largely limited
by very low yield in routine culture conditions, especially
theMSC-exosomes. Thus, there is a great need to develop
approaches to improve their yield without sacrificing
their functionality while, ultimately, enhancing their effi-
cacy as well. A study showed exosomes isolated from
neuron-CM-contained small RNA that were internalised
into astrocytes to improve its signalling in amyotrophic
lateral sclerosis mice model [36]. Another study showed
MSCs exposed to ischemic brain extracts had increased
levels of miR-133b in its released exosomes [38].
Therefore, refining the culture condition of MSCs will
significantly influence not only the production yield but
also the efficacy ofMSC-exosomes in consideration to the
proteomic and genomic complexities of exosomes [40–
44]. The culture condition alone may not be enough to
address the additional limitations on the efficacy of MSC-
exosomes though. Exosomes derived from different cell
types may have preferential targeting towards certain cell
types based on theirmembrane composition thus impart-
ing a differential effect on body systems [37,41,45]. For
example, oligodendroglia EVs are preferentially taken up
by microglia [36]. This could be addressed by exploiting
the nature of exosomes as natural carriers of miRNA or
other molecules by treating them as drug delivery vehicles
as their counterparts, liposomes or extracellular nanove-
sicles, are currently utilised [40,42,45,46]. To exemplify
this, modified exosomes containing therapeutic cargo are
currently under use in clinical trials [46].
Three-dimensional extracellular matrix-based
scaffolds
MSCs are usually cultured on two-dimensional (2D)
plastic tissue culture dishes and flasks, limiting the
surface area for cell growth as well as cell–cell and
cell–extracellular matrix interaction in the living envir-
onment, which does not truly represent the in vivo
conditions. Native extracellular matrix (ECM) can be
utilised to provide a three-dimensional (3D) environ-
ment for cell attachment and growth while synthetic
biomaterial scaffolds can be engineered to mimic the
ECM structure and functions. The native ECM can be
developed by decellularising tissues to achieve a hetero-
geneous composition of extracellular molecules left
from decellularised tissues. Cells can bind to those
molecules via surface receptors, providing a direct
interaction that could potentially influence their func-
tionality. Functional EVs can also be derived from
native ECM and promote cell functions [47,48]. The
native ECM can come in the forms of a hydrogel, a
sheet or a porous scaffold and they can be utilised for
MSC culture to generate the EVs [49] (Figure 3).
Scaffold structure could influence the functions of
seeded cells. When a hydrogel, a porous scaffold of the
alginate solution (derived from brown algae) and a
tissue culture plastic surface were compared, it was
found that the porous scaffold allowed the highest
concentration of cytokines and growth factors pro-
duced by bone marrow MSCs (BM-MSCs) compared
to the other surfaces [49]. Concentrations of cytokines
basic fibroblast growth factor 2, insulin-like growth
factor, hepatocyte growth factor and leukaemia inhibi-
tory factor were significantly higher in the CM derived
from the porous scaffold compared to CMs derived
from hydrogel and tissue culture surface. Such struc-
ture could also influence EV secretion and possibly
their therapeutic potential since the MSCs are known
to be responsive to the environmental stimuli.
Similarly, it was shown that the Avitene Ultrafoam
collagen hemostat caused the BM-MSCs to release
twice the number of exosomes compared to the plastic
surface culture based on the protein assay [32].
Although the isolation method used in this study was
precipitation with no further purification, the concept
itself may be beneficial to finding a way to increase the
MSC-exosome yield. Moreover, those exosomes
derived from the 3D condition had greater therapeutic
effects on the rat model of traumatic brain injury,
causing superior cognitive functional recovery when
directly injected into rat brains. Additionally, the
matrix scaffold could also be used as a delivery vehicle
for exosomes to achieve local and prolonged delivery to
the wound area [32]. In a diabetic rat model, the
chitosan wound dressing was used as an exosome
delivery vehicle over a course of 6 days, allowing for
acceleration of re-epithelialisation, angiogenesis and
collagen maturity of the wound sites [32].
Unlike the native ECM, the synthetic matrices do
not possess the functional molecules, but they can be
modified by adding molecules in order to make more
of a bioactive artificial ECM. This modification will
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also circumvent the potential issues of native matrices
such as batch-to-batch or donor-to-donor variations. A
variety of advanced engineering approaches have been
used to produce native ECM mimicking structures. For
example, an ECM mimicking nanofibrous scaffold
could be created by electrospinning from polymer
blends of polylactic acid (PLA) and polycaprolactone
(PCL) [31]. At the same time, such a scaffold could be
potentially functionalised by presenting specific func-
tional ligands to improve production of MSC-exo-
somes [31]. Another advantage of the synthetic
scaffold is the control over their structural pattern
and composition. The fibres could be produced in
random, aligned or mesh-like patterns, and these dif-
ferent patterns were shown to affect MSCs in terms of
their secretome, such as increasing the production of
anti-inflammatory and pro-angiogenic factors [50].
Concentration of molecules prostaglandin E2, induci-
ble nitric oxide synthases, tumour necrosis factor-sti-
mulated gene 6 protein, transforming growth factor
beta 1, hepatocyte growth factor and vascular endothe-
lial growth factor increased significantly on the
oriented fibres compared to the microplate [50]. The
production of EVs as an important part of secretome
may be reflected by this approach as well. The compo-
sition of the synthetic scaffold could be adjusted to
improve the production of EVs in MSCs. It was
shown that by adding nitric oxide (NO) to a chitosan
scaffold, the resulting nitric oxide-releasing chitosan
scaffold caused placenta MSCs to release more exo-
somes with pro-angiogenic and pro-migratory factors
compared to the normal human placenta MSCs [47].
Specifically, vascular endothelial growth factor concen-
tration and microRNA 126 expression levels were
higher in the exosomes from the nitric oxide stimu-
lated placenta MSCs. The ischemic muscle tissue was
found to be extensively protected when those exosomes
were used as a treatment in the murine hind limb
ischemia model. Further studies are needed to discover
more well-defined molecules to functionalise the syn-
thetic scaffold that could induce MSCs to generate
more defined populations of EVs with specific biologi-
cal functions.
Large-scale cell expansion methods
As research continues to foray into utilising the 3D
environment for cell culture, there also emerges the
potential of expanding the cells within a small volume.
By making use of ECM, the limited surface area can be
maximised for its EV yield, but the number may still
not be enough for large-scale needs for clinical use.
Large volumes of media would be required to get a
sizable number of vesicles from the MSC-CM that
would meet clinical standards. Both the microcarriers
and hollow-fibre bioreactors have larger surface area
and are currently used for large-scale expansion of
MSCs in a 3D environment [51–57] (Figure 4).
The microcarriers are tiny beads with many varying
features such as material, pore size, and surface charge
[53]. The cells, adhered on microcarriers, are grown in
spinner flasks that hold a pair of plastic baffles in an X
formation propelled by a magnetic field, creating a
dynamic environment. The flasks also come in differ-
ent sizes, ranging from 100 mL to 3 L and are placed
Figure 3. The different forms of an extracellular matrix and their interactions with the cells. The tissue culture treated plastic surface
is the most common surface for culturing the MSCs (A). The ECM sheet can be in form of decellularised native ECM or an artificial
matrix, which can include different oriented fibres (B). A hydrogel can be manufactured from the decellularised ECM or a chemical
mixture for culturing seeded or encapsulated MSCs (C). The porous scaffold is the most similar to the native environment of the
MSCs, perhaps allowing the most suitable culture environment (D).
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on stir plates within an incubator where gas exchange
occurs by either the loosened side caps or by a gas line
through the holes on the side caps. Using this method,
the final cell yield is quite high and can be achieved
within a shorter incubation time. MSCs cultured using
this method show no change in differentiation capabil-
ity and maintain a normal karyotype [52–55]. The CM
collected from the suspension culture was shown to
contain higher levels of secretory molecules, which
increased the cell proliferation and neural differentia-
tion when injected directly to the hippocampal dentate
gyrus of rat brains [55]. The CM also enhanced both
the survival and differentiation rates of human neural
precursor cells in culture [52]. A drawback to this
method is that the cells are much more metabolically
active, thus more nutrients are consumed, and more
wastes are produced, requiring frequent change of cul-
ture media and passaging. Nevertheless, this could be
one of the promising methods to increase MSC-exo-
somes production with less culture media.
The hollow-fibre bioreactor is based on culturing
the cells in the hollow and semi-permeable fibres
[51,56,57]. The fibres are tube-like and approximately
200 microns in diameter. They are sealed in a glass
cylinder with inputs and outputs where media, waste
and gas flow through the cylinder in one direction. The
exchange of necessities that the cells require is achieved
with the porous barriers of the fibres. Similar to the
spinner flask, the hollow-fibre bioreactor can also
achieve a higher cell yield in a short incubation time.
Additional advantages would be less labour, as a com-
puter could maintain the necessities, and less risk of
contamination, as there is a significant decrease with
open procedures. Studies have been completed to
ensure that the hollow-fibre bioreactor would meet
the Good Manufacturing Practice standards and the
requirements of any clinical trial protocol [51,56]. By
scaling up the cell culture properly, the exosome yield
could increase without significantly compromising
their functionality.
Utilising the biology behind the extracellular vesicle
biogenesis
By utilising our current knowledge on the regulation
of EV biogenesis, we can manipulate certain compo-
nents that could lead to increased yield, particularly
the exosomes via the endolysosomal pathway. By
changing the intracellular milieu, we can potentially
manipulate the production of exosomes to increase
the final yield. For example, we can look at the
cellular components involved in beginning, middle
and/or end of the endolysosomal pathway, starting
with the P2X7 receptors on the membrane. The acti-
vation of P2X7 receptors (P2X7R) in pulses on the
membrane can trigger a number of cellular functions
such as membrane blebbing, sorting of endosomal
contents and fusion with the multivesicular body to
release the exosomes [58]. Another receptor of inter-
est can be the soluble NSF attachment protein recep-
tors (SNARES) which are required for fusion of the
multivesicular body to the plasma membrane [26,59–
61]. There are also multipass membrane proteins that
could regulate the exosome release such as the
tumour suppressor activated pathway-6 (TSAP6),
which is a p53-inducible gene. This was confirmed
when TSAP6-null mice showed a severe
Figure 4. The schematics of spinner flask containing microcarriers containing the cells (A) as well as the hollow-fibre bioreactor and
its cross section with cells inside (B).
6 J. PHAN ET AL.
compromised exosome secretion and their p53-
dependent secretory pathway abrogated [62,63]. This
pathway is also a substrate of a protein that provides
negative feedback to exosome secretion, rhomboid
domain containing 1 (RHBDD1) protein [64]. The
inactivation of the RHBDD1 protein prevented the
cleavage of transmembrane proteins, products of
TSAP6. These proteins are part of the exosome traf-
ficking activity, perhaps through mediation of move-
ment of the multivesicular body to the plasma
membrane, therefore, preventing their cleavage
could allow for more exosomes to be released. The
modulating lipids may be of interest as well, such as
the phospholipase D2 gene (PLD2). What PLD2 does
is breaking down phosphatidylcholine into choline
and phosphatidic acid, which is one of the important
lipid secondary messengers involved in endocytosis
and exocytosis processes. A study found that the
overexpression of PLD2 led to twice the number of
exosomes released from the cells while the knock-
down of PLD2 led to twice the amount lower than
exosomes released [65]. Another component of the
EV biogenesis that could be of interest is the multi-
vesicular body fusion with the plasma membrane and
its regulatory molecules such as the Rab protein
family along with their GTPases [66]. The Rab
GTPases are known for their roles in membrane
trafficking activity, which are part of the endosomal
system. With the inhibition of the Rab35 protein, the
cell has an accumulation of the endosomal vesicles
and an impaired secretion mechanism [66].
Evidently, the exosome secretion is compromised as
well. Perhaps finding another release mechanism,
such as Rab27a/b [67], to compensate for the
impaired secretion mechanism would allow for
those accumulated EVs to be secreted out of the
cells, leading to an increased yield.
Genetic packaging of the extracellular vesicles
By utilising our current knowledge on contents of the
EVs especially exosomes, we can improve their efficacy
such as changing what is packaged into them. This
modification can be achieved by overexpression of
certain proteins or have certain RNAs packed within
the exosomes.
Sequences such as DNA or RNA have been shown to
display neuroprotective or angiogenic properties. They can
be packed inside exosomes or directed to the exosomes
[9,68–74]. For example, protein kinase b (Akt) has been
shown to display angiogenic properties so when the AKT1
gene was transfected into MSCs, the exosomes derived
from Akt-modified MSCs promoted endothelial cell pro-
liferation, migration and new blood vessel formation in the
rat model of myocardial infarction [69]. Apart from acti-
vation of particular genes, overexpression of certain genes
that are already present in MSCs also provides some ben-
efits. For example, the hypoxia inducible factor-1α (HIF-
1α) has been shown to have angiogenic functions and is
present in MSCs [9]. Upon the overexpression of HIF-1α,
Jagged1 was found to be more abundant in exosomes
derived from the same MSCs, leading them to be pro-
angiogenic as well. This finding was proven when they
were used as a treatment for themurinemodel of ischemia.
Aside from the DNA sequences, RNA sequences could
serve as powerful therapeutic agents. Certain miRNAs
have been overexpressed in MSCs, causing an increase in
their levels within exosomes and in turn enhancing their
therapeutic potential. For example, the miR-30b and miR-
126 were overexpressed in MSCs, and the exosomes
derived from the culture were shown to promote angio-
genesis in various ischemia models and in the diabetic
wound model [18,32]. The exosomes derived from BM-
MSCs with miR-133b overexpression were shown to sig-
nificantly promote functional recovery in the rat model of
stroke [72]. There are also non-coding RNAs present in the
MSC-exosomes that have regulatory roles in reparation of
the damaged tissues [68].
Conclusion
MSC-exosomes are currently a hot topic as much
research is being conducted regarding their use as a
treatment for a myriad of diseases and disorders. There
are many advantages of using EVs, such as being a cell-
free alternative therapy, providing easier administra-
tion for patients and possibly requiring less time for
recovery. There are certain limitations though, one of
which is the isolation and purification of the EVs. The
resulting products remain heterogeneous, containing
non-EVs contaminants or too little vesicles for treat-
ment. The mechanism on how the EVs function as
paracrine remains elusive as more research is looking
into their specific contents and functions. With that
being said, any treatment using exosomes would need
to be evaluated extensively for safety and efficacy
before clinical trials [75]. A way to meet the potentially
high demand for exosomes derived from different
sources would also need to be developed. We herein
have described ways to manipulate both the outside
(extracellular) environment and the inside (intracellu-
lar) components of MSCs to increase the quantity of
exosomes and/or to improve their quality, which will
eventually lead to generating a uniform population of
exosomes that can potentially be used for future clin-
ical applications.
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